Sorafenib use in elderly patients with hepatocellular carcinoma: caution about use of platelet aggregation inhibitors.

Julien Edeline,Laurence Crouzet,Samuel Le Sourd,Claire Larible,Angélique Brunot,Florence Le Roy,Catherine Cattenoz,Marianne Latournerie,Daniel Gedouin,Anne Guillygomarc’h,Eveline Boucher

Sorafenib use in elderly patients with hepatocellular carcinoma: caution about use of platelet aggregation inhibitors.

2015

Julien Edeline
Laurence Crouzet
Samuel Le Sourd
Claire Larible
Angélique Brunot
Florence Le Roy
Catherine Cattenoz
Marianne Latournerie
Daniel Gedouin
Anne Guillygomarc’h
Eveline Boucher

Purpose Sorafenib is the standard of care for advanced hepatocellular carcinoma (HCC). The peak incidence of HCC is around 70 years. We aimed to evaluate safety and efficacy of sorafenib in the elderly population.

Keywords:

Oncology
Carcinoma
Hepatocellular carcinoma
Platelet aggregation inhibitor
Pharmacology
Survival analysis
Population
Retrospective cohort study
Sorafenib
Surgery
Diabetes mellitus
Internal medicine
Medicine
Comorbidity

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations